The 3 analysts offering 12-month price forecasts for Acer Therapeutics Inc have a median target of 8.00, with a high estimate of 10.00 and a low estimate of 4.00. The median estimate represents a +104.08% increase from the last price of 3.92.
The current consensus among 6 polled investment analysts is to Buy stock in Acer Therapeutics Inc. This rating has held steady since November, when it was upgraded from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.47
Reporting Date Mar 12
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.